1-4 of 4
Lucy J. Elrick
Close
Sort by
Journal Articles

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Mhairi Copland, Ashley Hamilton, Lucy J. Elrick, Janet W. Baird, Elaine K. Allan, Niove Jordanides, Martin Barow, Joanne C. Mountford, Tessa L. Holyoake
Journal: Blood
Blood (2006) 107 (11): 4532–4539.
https://doi.org/10.1182/blood-2005-07-2947
Published: 2006
Journal Articles

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Mhairi Copland, MD, Ashley Hamilton, BSc, Janet W. Baird, PhD, Martin Barow, PhD, Elaine K. Allan, BSc, Lucy J. Elrick, PhD, Tessa L. Holyoake, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 695.
https://doi.org/10.1182/blood.V106.11.695.695
Published: 2005
Journal Articles

Punish the parent not the progeny

Lucy J. Elrick, Heather G. Jorgensen, Joanne C. Mountford, Tessa L. Holyoake
Journal: Blood
Blood (2005) 105 (5): 1862–1866.
https://doi.org/10.1182/blood-2004-08-3373
Published: 2005
Journal Articles

Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro .

Lucy J. Elrick, PhD, Ashley Hamilton, BSc, Michael W. Deininger, MD PhD, Tessa L. Holyoake, MD PhD
Journal: Blood
Blood (2004) 104 (11): 1979.
https://doi.org/10.1182/blood.V104.11.1979.1979
Published: 2004